| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $150.2M | — | +262.8% |
| SG&A Expense | $14.0M | — | -0.7% |
| Operating Income | -$164.1M | — | -195.9% |
| Net Income | -$158.3M | — | -247.0% |
| EPS (Basic) | -$1.37 | — | -234.1% |
| EPS (Diluted) | -$1.37 | — | -234.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $118.1M | -28.8% | +211.3% |
| Current Assets | $608.2M | -15.0% | -29.8% |
| Total Assets | $608.2M | -15.0% | -29.8% |
| Current Liabilities | $106.3M | +38.7% | +443.2% |
| Total Liabilities | $106.3M | +38.7% | +429.6% |
| Stockholders' Equity | $501.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$114.0M | — | -117.8% |
| Investing Cash Flow | $54.2M | — | -14.3% |
| Financing Cash Flow | $12.1M | — | +3360.5% |
| -40.7% |